Geyser Brands Inc.

TSXV Exchange | Jul 3, 2020, 10:01 PM EDT | Real-time price

GYSR $ 0.14 RT
-0.02 (-12.50%)
Day Low: 0.14
Day High: 0.14
Geyser Brands Awarded Sales License from Health Canada

(via TheNewswire)

June 15, 2020 - TheNewswire - Vancouver, BC - Geyser Brands Inc. (TSXV:GYSR) (OTC:GYSRF) ("Geyser Brands" or the "Company) is pleased to announce that the Company's subsidiary, 0957102 B.C. Ltd. DBA Apothecary Botanicals ("Apothecary Botanicals"), has been awarded by Health Canada its full sales license.

With the awarded licenses, Geyser Brands will manufacture, distribute and sell Cannabis containing topicals, edibles, and beverages related directly to medical patients and to provincial distributors across Canada. In anticipation of these licenses, the Company has already developed and registered with Health Canada a portfolio of Cannabis 2.0 products, including teas and coffees, tinctures, sprays and extracts, and chocolates and gummies.

The Company's most immediate focus is in topicals, where it is has manufacturing capacity to produce gels and creams in tubes, roll-on containers and jars. Its first product is a CBD/THC roll-on gel intended for the pain relief market, and which it will start delivering in the second half of June. These products will be manufactured for Geyser portfolio brands such as Apothecary Labs, and for 3rd party white labels.

Kuldip Gill, Chief Operating Officer at Apothecary Botanicals, commented, "We are thrilled to announce that we have been awarded our remaining Sales Licenses from Health Canada. We now have the opportunity to connect our products and manufacturing more directly to consumers. We look forward to working with some of our existing and new partners to extend their product ranges through our manufacturing, and to monetizing their customer base through our new distribution capability"

Click Image To View Full Size

About Geyser Brands

Geyser Brands Inc. develops consumer product brands in the health and wellness sector that use hemp and CBD as a value-added ingredient. These involve next-generation formulas that focus on the mix of cannabinoids for specific conditions such as insomnia, anxiety and pain.

Proprietary delivery technologies include all natural nano-technology, slow-release mechanisms and non-molecule degrading baking processes. In anticipation of coming edibles legislation, and with its Health Canada approved Licensed Production Facility, Geyser Brands has 15,000 square feet in two GMP facilities in Vancouver, BC.

For more information, visit Geyser Brands' website at

On Behalf of the Board of Directors

"Andreas Thatcher"


Andreas Thatcher

Director and CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Forward-looking statements and information are often, but not always, identified by the use of words such as "appear", "seek", "anticipate", "plan", "continue", "estimate", "approximate", "expect", "may", "will", "project", "predict", "potential", "targeting", "intend", "could", "might", "should", "believe", "would" and similar expressions.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the risks associated with the marijuana industry in general such as operational risks in growing; competition; incorrect assessment of the value and potential benefits of various transactions; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and government regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information relating to Geyser is available at

Copyright (c) 2020 TheNewswire - All rights reserved.

Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. View delay times for all exchanges. Market Data powered by QuoteMedia. See the QuoteMedia Terms of Use.